alpha-Linolenic Acid
In clinical developmentAlso known as ALA, LINOLENIC ACID, Octadecatrienoic acid, Alpha linolenic acid+8 more
ALA, LINOLENIC ACID, Octadecatrienoic acid, Alpha linolenic acid, (9,12,15)-linolenic acid, (9Z,12Z,15Z)-Octadecatrienoic acid, (Z,Z,Z)-9,12,15-octadecatrienoic acid, 9,12,15-Octadecatrienoic acid, 9-cis,12-cis,15-cis-octadecatrienoic acid, all-cis-9,12,15-Octadecatrienoic acid, cis,cis,cis-9,12,15-Octadecatrienoic acid, cis-delta(9,12,15)-Octadecatrienoic acid.
Recent clinical, regulatory, research and industry developments relating to this drug.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- International journal of molecular sciences1
- Girek Z1
- Jovanović P1
- Jovanović V1
- Pavlović S1
- Ranković S1
- Šarac I1
- Takić M1
- Centre of Research Excellence in Nutrition and Metabolism1
- Department of Biochemistry and Centre of Excellence for Molecular Food Sciences1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials